Outros

<p>Applications Tetramethylurea is an excellent solvent for organic substances, in particular aromatic compounds.<br>References Lüttringhaus, A., et al.: Angew. Chem. Int. Ed. Engl., 3, 260 (1964)<br></p>

<p>Applications A glucuronide of (Z)-4-Hydroxy Tamoxifen (or trans-4-hydroxytamoxifen), an active metabolite of Tamoxifen (T006000).<br>References Beaulieu, M., et al.: J. Biol. Chem., 271, 22855 (1996), Green, M., et al.: Drug Metab. Dispos., 26, 860 (1998), Nishiyama, T., et al.: Biochem. Pharmacol., 63, 1817 (2002),<br></p>

<p>Applications N-Nitrosoatenolol is an N-nitroso derivative of Atenolol (A790075), which is a cardioselective β-adrenergic blocker. Antihypertensive, antianginal, antiarrhythmic (class II). N-Nitrosoatenolol can be used for its genotoxic effect in rat and human hepatocytes.<br>References Caplar, V., et al.: Anal. Profiles Drug Subs., 13, 1 (1984); Robbiano, L., et.al., Cancer Res., 51, 2273-2279, (1991);<br></p>

<p>Stability Hygroscopic<br>Applications d-Cloprostenol Sodium Salt is the d-enantiomer of Cloprostenol (C587300), an aryl-oxymethyl analog of prostaglandin F2α.<br>References Gumen, A., et al.: J. Animal. Sci., 56, 279 (2011); Leterlier, C.A., et al.: Reproduct. Domestic. Animals., 46, 481 (2011); Martins, J.P.N., et al.: J. Diary. Sci., 94, 2815 (2011);<br></p>

<p>Impurity Atenolol EP Impurity E<br>Applications 4,4'-[(2-Hydroxy-1,3-propanediyl)bis(oxy)]bis-benzeneacetamide is an impurity of Atenolol (A790075), a cardioselective β-adrenergic blocker. Atenolol EP Impurity E<br>References Caplar, V., et al.: Anal. Profiles Drug Subs., 13, 1 (1984);<br></p>

<p>Impurity Fulvestrant EP Impurity B<br>Applications A metabolite of Fulvestrant (F862500).<br>References Rao, P., et al.: J. Steroid Biochem., 25, 417 (1986), Wakeling, A., et al.: J. Steroid Biochem. Mol. Biol., 43, 173 (1992), DeFriend, D., et al.: Cancer Res., 54, 408 (1994),<br></p>

<p>Applications An intermediate in the production of Bimatoprost (B386800).<br></p>

<p>Applications N-Formyl Memantine is an impurity of Memantine (M218000). Memantine impurity E per USP.<br>References Gerzon, K., et al.: J. Med. Chem., 6, 760 (1963),<br></p>

<p>Applications (E)-Isomer of labelled Entacapone polymorphic form A. Peripherally acting inhibitor of catechol-O-methyl transferase (COMT), an enzyme involved in the metabolism of catecholamine neurotransmitters and related drugs. Antiparkinsonian.<br>References Karlsson, M., et al.: J. Pharm. Biomed. Anal., 10, 593 (1992), Nissinen, E., et al.: Arch. Pharmacol., 346, 262 (1992), Wikberg, T., et al.: Eur. J. Drug Metab. Pharmacokinet., 18, 359 (1993),<br></p>

<p>Applications Labelled Bimatoprost (B386800). Bimatoprost is an antiglaucoma agent. Bimatoprost is an synthetic prostamide; structurally related to prostaglandin F2α.<br>References Brandt, J.D., et al.: Ophthalmology, 108, 1023 (2001), Woodward, D.F., et al.: J. Pharmacol. Exp. Ther., 305, 772 (2003), Quinones, R., et al.: J. Ocul. Pharmacol. Ther., 20, 115 (2004),<br></p>

<p>Applications Perfluorophenol is used in the synthesis of PGA-films as biodegradable polymers. It also participates in the synthesis of tripod macrocyclic Gd(III) chelates for cancer molecular MRI.<br>References Lee, K. et al.: Langmuir., 20, 2531 (2004); Zhou, Z. et al.: Biomater., 34, 7683 (2013);<br></p>

<p>Impurity Diazepam EP Impurity E<br>Applications 6-Chloro-1-methyl-4-phenyl-2(1H)-quinazolinone (Diazepam EP Impurity E) is an impurity of Temazepam (T017200), which is a pharmacologically active metabolite. It is used as a sedative and hypnotic drug.<br>References Sarteschi, P., et al.: Arzneim.-Forsch., 22, 93 (1972), Schwandt, H.J., et al.: Xenobiotica, 4, 733 (1974), Curry, S.H., et al.: Br. J. Pharmacol., 57, 427 (1976), Heel, R.C., et al.: Drugs, 21, 321 (1981)<br></p>

<p>Applications Salicylic Acid β-D-O-Glucuronide is a metabolite of Acetylsalicylic Acid (Aspirin) (A187780).<br>References Grootveld, M., et al.: Biochem. Pharmacol., 37, 271 (1988), Subbegowda, R., et al.: Cancer Res., 58, 2772 (1998), Yoshida, Y., et al.: Eur. J. Pharmacol., 349, 49 (1998),<br></p>

<p>Applications (15R)-Bimatoprost Acid is an impurity of the antiglaucoma agent Bimatoprost (B386820). (15R)-Bimatoprost Acid is a metabolically stable analog of PGF2α (P838625) and is a potent agonist for the FP receptor.<br>References Balapure, A.K. et al.: Biochem. Pharmacol., 38, 2375 (1989); Hellberg, M.R. et al.: J. Ocular Pharmacol. Ther., 19, 97 (2003); Krishna, P.M. et al.: J. Pharm. res., 4, 2381 (2011); Resul, B., et al.: J. Med. Chem., 36, 243 (1993)<br></p>

<p>Applications Cyancobalamin-b-carboxylic Acid is a Vitamin B12 (V676005) derivative, which is a water-soluble vitamin with a key role in the normal functioning of the brain and nervous system, and for the formation of blood.<br>References Rickes, et al.: Science, 107, 396 (1948); Kirschbaum, J., et al.: Anal. Profiles Drug Subs., 10, 183 (1981); Grasbeck, R., et al.: Clin. Biochem., 17, 99 (1984)<br></p>

<p>Applications Cardioselective β-adrenergic blocker. Antihypertensive, antianginal, antiarrhythmic (class II).<br>References Caplar, V., et al.: Anal. Profiles Drug Subs., 13, 1 (1984),<br></p>

<p>Applications A labelled β-adrenergic agonist, related to Clenbuterol and Mabuterol. A repartitioning agent.<br>References Engelhardt, G., et al.: Arzneim.-Forsch., 34, 1625 (1984),<br></p>

<p>Applications The primary metabolite of Diazepam. A ligand for the GABAA receptor benzodiazepine modulatory site. Anxiolytic.Controlled substance (depressant).<br>References Klotz, U., et al.: Br. J. Clin. Pharmacol., 7, 119 (1979), Konishi, M., et al.: J. Pharm. Sci., 67, 1777 (1978), Andreoli, V., et al.: Arzneim.-Forsch., 27, 436 (1977), Miller, R.P., et al.: Toxicol. Appl. Pharmacol., 25, 453 (1973), Margolis, J., et al.: Drug Metab. Dispos., 31, 606 (2003),<br></p>

<p>Applications N-(3-(3-Cyano-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidin-5-yl)phenyl)-N-ethylacetamide is an impurity of Zaleplon (Z145000), Selective non-benzodiazepine GABAA receptor agonist.<br>References Allen, D., et al.: Eur. J. Clin. Pharmacol., 45, 313 (1993), Beer, B., et al.: J. Clin. Pharmacol., 34, 335 (1994), Rosen, A.S., et al.: Biopharm. Drug Dispos., 20, 171 (1999), Elie, R., et al.: J. Clin. Psychiatry, 60, 536 (1999), Heydorn, W.E., et al.: Expert Opin. Invest. Drugs, 9, 841 (2000)<br></p>